Plain-English translation of NCT05836259 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hypertrophic Cardiomyopathy research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is an early-stage clinical trial testing TN-201, a gene therapy designed to treat a specific type of inherited heart disease called hypertrophic cardiomyopathy. The therapy works by delivering a corrective gene directly into heart muscle cells. Researchers will monitor participants closely over 5 years to understand whether the treatment is safe and how well it works.
Hypertrophic cardiomyopathy caused by MYBPC3 gene mutations can cause heart muscle to thicken abnormally, leading to shortness of breath, chest pain, and other serious symptoms. This medication represents a new approach—using gene therapy instead of traditional medications—to potentially address the root genetic cause of the disease.
You likely qualify if…
You likely don't qualify if…
If enrolled, you will receive a single dose of the medication delivered through an injection into a coronary artery (similar to a cardiac catheterization procedure). You will then return for regular clinic visits and heart imaging tests over the next 5 years to monitor your heart's function and watch for any side effects. The study involves blood tests, heart scans, and symptom assessments to track how your body responds to the therapy.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States